Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series
Pigment Cell & Melanoma Research · 2024
DOI: 10.1111/pcmr.13186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, 2024. Verfasst von Iris Dirven und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel)/Vrije Universiteit Brussel (VUB), Brussels, Belgium. Hauptthemen laut MEDLINE: Melanoma, Biomarkers, Tumor, Meningeal Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAF V600 ‐ and NRAS Q61 ‐mutant cell‐free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. In 12 patients with clinical suspicion of LMM, a retrospective analysis of MRI, CSF cytology and cfDNA analysis on 1 mL of CSF using the Idylla® platform was carried out. Nine patients displayed MRI abnormalities suggesting LMM. CSF analysis identified malignant cells in three patients (including one without MRI abnormalities). BRAF V600 ‐ or NRAS Q61 ‐mutant cfDNA was detected in CSF of nine patients (eight with and one without MRI abnormalities; all patients with positive CSF cytology). Subsequent follow‐up confirmed LMM in all patients with positive and in one patient with a negative CSF cfDNA analysis (sensitivity 81.8%; specificity 100%). Our findings suggest that analyzing BRAF V600 ‐ and NRAS Q61 ‐mutant cfDNA in CSF using the Idylla® platform holds promise as a sensitive and specific complementary diagnostic biomarker for LMM, particularly in case of inconsistency between imaging and CSF cytology. The 110‐min analysis can facilitate urgent treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel)/Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Department of Medical Oncology, Algemeen Ziekenhuis Sint-Lucas, Brugge, Belgium.
- Department of Radiology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
ORCID-Profile: Iris Dirven
Zitieren
APA
Dirven, I., Vounckx, M., Kessels, J. I., Lauwyck, J., Awada, G., Vanbinst, A. M., & Neyns, B. (2024). Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.13186
Vancouver
Dirven I, Vounckx M, Kessels JI, Lauwyck J, Awada G, Vanbinst AM, et al. Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series. Pigment Cell & Melanoma Research. 2024. doi:10.1111/pcmr.13186
BibTeX
@article{Dirven2024,
author = {Dirven, Iris and Vounckx, Manon and Kessels, Jolien I and Lauwyck, Justine and Awada, Gil and Vanbinst, Anne-Marie and Neyns, Bart},
title = {Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series},
journal = {Pigment Cell & Melanoma Research},
year = {2024},
doi = {10.1111/pcmr.13186}
}
EUVIMED